The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

Authors :: Paul W. H. I. Parren
Shulamiet Wittebol
Joost M. Bakker
H M Lokhorst
M de Weers
Tuna Mutis
M S van der Veer
B van Kessel
Medical oncology laboratory
Medical psychology
NCA - Hormones and the Brain
Hematology
Hematology laboratory
Source :: Blood cancer journal, 1(10):e41. Nature Publishing Group, Van Der Veer, M S, De Weers, M, Van Kessel, B, Bakker, J M, Wittebol, S, Parren, P W H I, Lokhorst, H M & Mutis, T 2011, ' The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies ', Blood cancer journal, vol. 1, no. 10, e41 . https://doi.org/10.1038/bcj.2011.42, Blood Cancer Journal
Publication Year :: 2011
Abstract: Multiple myeloma (MM) is an incurable malignancy of antibody-producing clonal plasma cells. The mean life expectancy of patients has remained at

Language :: English
ISSN :: 20445385
Database :: OpenAIRE
Journal :: Blood cancer journal, 1(10):e41. Nature Publishing Group, Van Der Veer, M S, De Weers, M, Van Kessel, B, Bakker, J M, Wittebol, S, Parren, P W H I, Lokhorst, H M & Mutis, T 2011, ' The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies ', Blood cancer journal, vol. 1, no. 10, e41 . https://doi.org/10.1038/bcj.2011.42, Blood Cancer Journal
Accession number :: edsair.doi.dedup.....362c3343e92cc1c4b33187fcea0b73e7
Full Text :: https://doi.org/10.1038/bcj.2011.42

Full Text Access

Tools